HIGHLIGHTS
- who: Antonia Resag and collaborators from the Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstrau00dfe, Dresden, Germany Department of Surgery Oncology and Gastroenterology, University of Padova, Via Gattamelata , have published the Article: The Immune Contexture of Liposarcoma and Its Clinical Implications, in the Journal: (JOURNAL)
- what: Since BO-112 was previously shown to induce local and systemic immunotherapeutic effects by increasing tumor cell apoptosis and enhancing immune reactivity, the primary objective of this study is to determine the safety and tolerability of adding BO-112 to nivolumab treatment (NCT04420975) . The trial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.